Author:
Sheean Maria E.,Naumann-Winter Frauke,Capovilla Giuseppe,Kalland Maria Elisabeth,Malikova Eva,Mariz Segundo,Matusevicius Darius,Nistico Robert,Schwarzer-Daum Brigitte,Tsigkos Stelios,Tzogani Kyriaki,Larsson Kristina,Magrelli Armando,Stoyanova-Beninska Violeta
Abstract
Since the implementation of the EU Orphan Regulation in 2000, the Committee for Orphan Medicinal Products at the European Medicines Agency has been evaluating the benefits of proposed orphan medicines vs. satisfactory treatment methods. This type of evaluation is foreseen in the Orphan Regulation as the orphan designation criterion called the “significant benefit.” In this article, based on 20 years of experience, we provide a commentary explaining what is considered a satisfactory method of treatment in the context of the EU Orphan Regulation and for the purpose of the assessment of significant benefit. We discuss the challenges posed by continuously changing clinical practise, which is associated with the increasing number of treatment options, evolving nature of medicinal therapeutic indications and our understanding of them.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献